Pentosidine

3242-v 1 mg | 115.00 EUR

(S)-2-Amino-6-(2-(((S)-4-amino-4-carboxybutyl)amino)-4H-imidazo[4,5-b]pyridin-4-yl)hexanoic acid
(Trifluoroacetate Form)

Synthetic Product
A trace of impurity might be detectable by TLC when 100 µg is applied to the plate. The amount of contamination detectable by HPLC is less than 2 %.

Advanced Glycation End Product (AGE) / Biomarker for Glycation-Oxidative Stress e.g. in Diabetes

References:

1. D.R. Sell and V.M. Monnier, J. Bio. Chem., 264, 21597 (1989) Original
2. T. Miyata, Y. Ueda, K. Horie, M. Nangaku, S. Tanaka, C.Y. Strihou, and K. Kurokawa, Kitney Int., 53, 416 (1998) (Pharmacol.)
3. D. Slowik-Żylka, K. Safranow, V. Dziedziejko, H. Bukowska, K. Ciechanowski, and D. Chlubek, J. Biochem. Biophys. Methods, 61, 313 (2004) (Specific determination of Pentosidine in plasma)
4. M. Saito and K. Marumo, Osteoporos. Int., 21, 195 (2010) (clinical review)
5. R. Furuya, H. Kumagai, T. Miyata, H. Fukasawa, S. Isobe, N. Kinoshita, and A. Hishida, Clin. Exp. Nephrol., 16, 421 (2012) (clinical; correlation to Cardiovascular risk)
6. M. Yamamoto and T. Sugimoto, Curr. Osteoporos. Rep., 14, 320 (2016) (Review)